Interacciones de Subcitrato de bismuto, metronidazol y tetraciclina

Subcitrato de bismuto, metronidazol y tetraciclina (Pylera), antibiótico, tiene 179 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 20; moderadas: 143; leves: 12; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 4. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (20)

  • AcitretinaretinoideGrave

    Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated (see WARNINGS: Pseudotumor Cerebri ). (etiqueta de Acitretina, Contraindicaciones)

  • AlcoholAlcoholGrave

    Alcoholic beverage consumption for at least three days during or after therapy. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Contraindicaciones)

  • Antiácidos (Tums, Maalox, Mylanta)Productos sin recetaGrave

    Antacids, Multivitamins or Dairy Products: Decreased absorption of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules; do not take concomitantly. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Bosentáninductor de CYP3A4Grave

    Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with TRACLEER is not recommended. (etiqueta de Bosentán, Interacciones medicamentosas)

  • Do not administer bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride concomitantly with busulfan unless the benefit outweighs the risk. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Demeclociclinaantibiótico del grupo de las tetraciclinasGrave

    CONTRAINDICATIONS This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or any of the components of the product formulation. (etiqueta de Demeclociclina, Contraindicaciones)

  • Dicloxacilinaantibiótico del grupo de las penicilinasGrave

    Drug Interactions Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided. (etiqueta de Dicloxacilina, Interacciones medicamentosas)

  • Disulfiraminhibidor de CYP2C9Grave

    Disulfiram usage within the last two weeks. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Contraindicaciones)

  • Doxiciclinaantibiótico del grupo de las tetraciclinasGrave

    Doxycycline hyclate are contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. (etiqueta de Doxiciclina, Contraindicaciones)

  • DronabinolcannabinoideGrave

    …reactions to dronabinol include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing, throat tightness [see Adverse Reactions ( 6.2 )] . with a history of a hypersensitivity reaction to alcohol. who are receiving, or have recently received, disulfiram- or metronidazole-containing products within 14 days [see Warning and Precautions ( 5.3 )] . (etiqueta de Dronabinol, Contraindicaciones)

  • IsotretinoínaretinoideGrave

    Concomitant use of isotretinoin should be avoided because isotretinoin is also known to cause IH. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Lácteos (leche, queso, yogur)Alimentos y bebidasGrave

    Antacids, Multivitamins or Dairy Products: Decreased absorption of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules; do not take concomitantly. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Avoid concomitant use of mebendazole and metronidazole ( 5.3 ) (etiqueta de Mebendazol, Advertencias y precauciones)

  • Minociclinaantibiótico del grupo de las tetraciclinasGrave

    EMROSI is contraindicated in patients with a history of hypersensitivity to any of the tetracyclines [see Warnings and Precautions (5.1) ]. (etiqueta de Minociclina, Contraindicaciones)

  • Nafcilinaantibiótico del grupo de las penicilinasGrave

    Drug Interactions Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided. (etiqueta de Nafcilina, Interacciones medicamentosas)

  • Oxacilinaantibiótico del grupo de las penicilinasGrave

    Drug Interactions Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided. (etiqueta de Oxacilina, Interacciones medicamentosas)

  • Penicilina Gantibiótico del grupo de las penicilinasGrave

    Drug Interactions Bacteriostatic antibacterials ( i.e. , chloramphenicol, erythromycins, sulfonamides or tetracyclines) may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided. (etiqueta de Penicilina G, Interacciones medicamentosas)

  • Tigeciclinaantibiótico del grupo de las tetraciclinasGrave

    Avoid use in patients with known hypersensitivity to tetracyclines. (etiqueta de Tigeciclina, Advertencias y precauciones)

  • TinidazolantibióticoGrave

    WARNING: POTENTIAL RISK FOR CARCINOGENICITY WARNING: POTENTIAL RISK FOR CARCINOGENICITY Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent [see Nonclinical Toxicology (13.1)]. (etiqueta de Tinidazol, Advertencia en recuadro)

Interacciones moderadas (143)

  • Acetato de calcioquelante de fosfatoModerada

    Calcium acetate capsules may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism. (etiqueta de Acetato de calcio, Interacciones medicamentosas)

  • AlfuzosinaalfabloqueanteModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • AmiodaronaantiarrítmicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Amitriptilinaantidepresivo tricíclicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Anagrelidafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • ApixabánanticoagulanteModerada

    Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • ArgatrobánanticoagulanteModerada

    Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • AsenapinaantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • AtovacuonaantipalúdicoModerada

    • Concomitant administration of tetracycline reduces atovaquone concentrations; use caution when coadministering. (etiqueta de Atovacuona, Interacciones medicamentosas)

  • Atovacuona y proguanilantipalúdicoModerada

    • Tetracycline may reduce atovaquone concentrations; parasitemia should be closely monitored. (etiqueta de Atovacuona y proguanil, Interacciones medicamentosas)

  • Avanafiloinhibidor de la PDE5Moderada

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (etiqueta de Avanafilo, Interacciones medicamentosas)

  • Azitromicinaantibiótico macrólidoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Bicarbonato de sodioantiácidoModerada

    …Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • BivalirudinaanticoagulanteModerada

    Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • CalcioVitaminas y mineralesModerada

    El calcio se une a estos fármacos en el intestino y puede reducir drásticamente la cantidad que se absorbe; separe las dosis. (NIH Office of Dietary Supplements, Calcium)

  • CarvedilolbetabloqueanteModerada

    Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (etiqueta de Carvedilol, Interacciones medicamentosas)

  • CelecoxibAINEModerada

    Co-administration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g., fluconazole) may enhance the exposure and toxicity of celecoxib whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of celecoxib. (etiqueta de Celecoxib, Interacciones medicamentosas)

  • CiclofosfamidainmunosupresorModerada

    Monitor for neurologic toxicities in patients receiving metronidazole. (etiqueta de Ciclofosfamida, Interacciones medicamentosas)

  • Cimetidinaantagonista H2Moderada

    Inhibitors of CYP450 liver enzymes The simultaneous administration of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride and drugs that inhibit microsomal liver enzymes, such as cimetidine, may result in a prolonged half-life and decreased plasma clearance of metronidazole. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • CiprofloxacinofluoroquinolonaModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • CitalopramISRSModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Claritromicinaantibiótico macrólidoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • CloroquinaantipalúdicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • ClorpromazinaantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • ClozapinaantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Colestipolsecuestrador de ácidos biliaresModerada

    The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride; these drugs were not tested to determine the effect of administration one hour before colestipol hydrochloride. (etiqueta de Colestipol, Interacciones medicamentosas)

  • Colestiraminasecuestrador de ácidos biliaresModerada

    Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (etiqueta de Colestiramina, Interacciones medicamentosas)

  • DabigatránanticoagulanteModerada

    Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Desogestrel y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Deutetrabenazinainhibidor de VMAT2Moderada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Dextrometorfano y quinidinafármaco serotoninérgicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Diacetato de etinodiol y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • DiclofenacoAINEModerada

    Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac whereas co- administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of diclofenac. (etiqueta de Diclofenaco, Interacciones medicamentosas)

  • Co-administration of diclofenac with CYP2C9 inhibitors (e.g., voriconazole) may enhance the exposure and toxicity of diclofenac [see Clinical Pharmacology (12.3) ] whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of diclofenac. (etiqueta de Diclofenaco y misoprostol, Interacciones medicamentosas)

  • DisopiramidaantiarrítmicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • DofetilidaantiarrítmicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • DronedaronaantiarrítmicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Droperidolantagonista de la dopaminaModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Drospirenona y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • EdoxabánanticoagulanteModerada

    Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (etiqueta de Elexacaftor, tezacaftor e ivacaftor, Interacciones medicamentosas)

  • EnoxaparinaanticoagulanteModerada

    Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Eritromicinaantibiótico macrólidoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • EscitalopramISRSModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • EstradiolestrógenoModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Estradiol y dienogestanticonceptivo oralModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Estradiol y noretisteronaestrógenoModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Estrógenos conjugadosestrógenoModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoModerada

    Inducers of CYP450 liver enzymes The simultaneous administration of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride and drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma concentrations of metronidazole. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoModerada

    Inducers of CYP450 liver enzymes The simultaneous administration of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride and drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma concentrations of metronidazole. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Inducers of CYP450 liver enzymes The simultaneous administration of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride and drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma concentrations of metronidazole. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • FingolimodinmunosupresorModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • FlecainidaantiarrítmicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Fluconazolantifúngico azólicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • FluoxetinaISRSModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • FondaparinuxanticoagulanteModerada

    Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • FulvestrantestrógenoModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • GlimepiridasulfonilureaModerada

    …antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides,… (etiqueta de Glimepirida, Interacciones medicamentosas)

  • Granisetrónfármaco que prolonga el intervalo QTModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • HaloperidolantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • HeparinaanticoagulanteModerada

    Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Hidroxicloroquinafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • HidroxizinaantihistamínicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • HierroVitaminas y mineralesModerada

    El hierro se une a estos fármacos en el intestino y reduce su absorción; separe las dosis. (NIH Office of Dietary Supplements, Iron)

  • IbutilidaantiarrítmicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • IloperidonaantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Ketoconazolantifúngico azólicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • LacosamidaanticonvulsivoModerada

    Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to VIMPAT. (etiqueta de Lacosamida, Interacciones medicamentosas)

  • Lantanoquelante de fosfatoModerada

    Examples of relevant classes of compounds where antacids have been demonstrated to reduce bioavailability include antibiotics (such as quinolones, ampicillin, and tetracyclines), thyroid hormones, ACE inhibitors, statin lipid regulators, and anti-malarials. (etiqueta de Lantano, Interacciones medicamentosas)

  • LevofloxacinofluoroquinolonaModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • LevonorgestrelprogestágenoModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Levonorgestrel y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Litiofármaco serotoninérgicoModerada

    Lithium In patients stabilized on relatively high doses of lithium, short-term use of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may cause elevation of serum lithium concentrations and signs of lithium toxicity due to the interaction between metronidazole and lithium. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • LomitapidaModerada

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etiqueta de Lomitapida, Advertencias y precauciones)

  • Loperamidafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • MagnesioVitaminas y mineralesModerada

    Los suplementos y los antiácidos que contienen magnesio reducen la absorción de estos fármacos; separe las dosis al menos dos horas. (NIH Office of Dietary Supplements, Magnesium)

  • MedroxiprogesteronaprogestágenoModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • MegestrolprogestágenoModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • MeloxicamAINEModerada

    Thus concomitant usage of CYP2C9 inhibitors (such as amiodarone, fluconazole, and sulphaphenazole) may lead to abnormally high plasma levels of meloxicam due to reduced metabolic clearance [ see Use in Specific Populations ( 8.8 ); and Clinical Pharmacology ( 12.3 , 12.5 ) ]. (etiqueta de Meloxicam, Interacciones medicamentosas)

  • MetadonaopioideModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • MetronidazolantibióticoModerada

    Warfarin and other Oral Anticoagulants Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (etiqueta de Metronidazol, Interacciones medicamentosas)

  • Mifepristonainhibidor de CYP3A4Moderada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • MoxifloxacinofluoroquinolonaModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • NateglinidameglitinidaModerada

    …salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid, and inhibitors of CYP2C9 (e.g., amiodarone, fluconazole, voriconazole, sulfinpyrazone) or in patients known to be poor metabolizers of CYP2C9 substrates, alcohol. (etiqueta de Nateglinida, Interacciones medicamentosas)

  • Nilotinibfármaco que prolonga el intervalo QTModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • NoretisteronaprogestágenoModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Noretisterona y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Norgestimato y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Norgestrel y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • OfloxacinofluoroquinolonaModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Olanzapina y fluoxetinaantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Omeprazol y bicarbonato de sodioinhibidor de la bomba de protonesModerada

    …Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • Ondansetrónfármaco que prolonga el intervalo QTModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • PaliperidonaantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Pentamidinafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • PimavanserinaantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • PimozidaantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Pioglitazona y glimepiridatiazolidinedionaModerada

    …antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides,… (etiqueta de Pioglitazona y glimepirida, Interacciones medicamentosas)

  • Pitolisantfármaco que prolonga el intervalo QTModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Posaconazolantifúngico azólicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • ProcainamidaantiarrítmicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • ProgesteronaprogestágenoModerada

    Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • PrometazinaantihistamínicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Prometazina y codeínaopioideModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Prometazina y dextrometorfanoantihistamínicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • QuetiapinaantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Quinaprilinhibidor de la ECAModerada

    Tetracycline and other drugs that interact with magnesium Simultaneous administration of tetracycline with quinapril hydrochloride reduced the absorption of tetracycline by approximately 28% to 37%, possibly due to the high magnesium content in quinapril tablets. (etiqueta de Quinapril, Interacciones medicamentosas)

  • QuinidinaantiarrítmicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • QuininaantipalúdicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Ramelteónsedante-hipnóticoModerada

    Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etiqueta de Ramelteón, Interacciones medicamentosas)

  • Ranolazinafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • RisperidonaantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • RivaroxabánanticoagulanteModerada

    Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Rocuroniobloqueador neuromuscularModerada

    Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as Rocuronium Bromide Injection include certain antibiotics (e.g., aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). (etiqueta de Rocuronio, Interacciones medicamentosas)

  • RosuvastatinaestatinaModerada

    Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (etiqueta de Rosuvastatina, Interacciones medicamentosas)

  • SolifenacinaanticolinérgicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • SotalolbetabloqueanteModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • SucralfatoModerada

    Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. (etiqueta de Sucralfato, Interacciones medicamentosas)

  • TacrolimusinmunosupresorModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Tamoxifenomodulador selectivo de los receptores de estrógenosModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Tetrabenazinainhibidor de VMAT2Moderada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Tetraciclinaantibiótico del grupo de las tetraciclinasModerada

    As with other antibacterial drugs, use of tetracycline hydrochloride may result in overgrowth of nonsusceptible organisms, including fungi. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • TioridazinaantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • TolterodinaanticolinérgicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Torasemidadiurético de asaModerada

    CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. (etiqueta de Torasemida, Interacciones medicamentosas)

  • Toremifenomodulador selectivo de los receptores de estrógenosModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • TramadolopioideModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Tramadol y paracetamolopioideModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • TrazodonaantidepresivoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • TretinoínaretinoideModerada

    The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (etiqueta de Tretinoína, Advertencias y precauciones)

  • Trióxido de arsénicofármaco que prolonga el intervalo QTModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Valbenazinainhibidor de VMAT2Moderada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Vardenafiloinhibidor de la PDE5Moderada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • VenlafaxinaIRSNModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Voriconazolantifúngico azólicoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • WarfarinaanticoagulanteModerada

    Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride is administered concomitantly with warfarin. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Zafirlukastantagonista de los receptores de leucotrienosModerada

    Zafirlukast exposure is likely to be increased by other moderate and strong CYP2C9 inhibitors. (etiqueta de Zafirlukast, Precauciones)

  • ZincVitaminas y mineralesModerada

    El zinc reduce la absorción de los antibióticos del grupo de las quinolonas y de las tetraciclinas; tome el antibiótico al menos dos horas antes o de cuatro a seis horas después del zinc. (NIH Office of Dietary Supplements, Zinc)

  • ZiprasidonaantipsicóticoModerada

    Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

Menciones leves (12)

  • Amoxicilinaantibiótico del grupo de las penicilinasLeve

    Other Antibacterials Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. (etiqueta de Amoxicilina, Interacciones medicamentosas)

  • Ampicilinaantibiótico del grupo de las penicilinasLeve

    Bacteriostatic Antibiotics : Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins. (etiqueta de Ampicilina, Interacciones medicamentosas)

  • Clopidogrelantiagregante plaquetarioLeve

    However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

  • Clotrimazolantifúngico azólicoLeve

    Development of Potential for Microbial Overgrowth Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with metronidazole and requires treatment with an antifungal agent. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Econazolantifúngico azólicoLeve

    Development of Potential for Microbial Overgrowth Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with metronidazole and requires treatment with an antifungal agent. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Ergotamina y cafeínaalcaloide ergóticoLeve

    Examples of less potent CYP 3A4 inhibitors include: saquinavir, nefazodone, fluconazole, fluoxetine, grapefruit juice, fluvoxamine, zileuton, metronidazole, and clotrimazole. (etiqueta de Ergotamina y cafeína, Advertencias)

  • InfliximabinmunosupresorLeve

    Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of CD including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates. (etiqueta de Infliximab, Interacciones medicamentosas)

  • Itraconazolantifúngico azólicoLeve

    Development of Potential for Microbial Overgrowth Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with metronidazole and requires treatment with an antifungal agent. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • Lopinavir y ritonavirantirretroviralLeve

    Disulfiram/metronidazole KALETRA oral solution contains ethanol, which can produce disulfiram-like reactions when co-administered with disulfiram or other drugs that produce this reaction (e.g., metronidazole). (etiqueta de Lopinavir y ritonavir, Interacciones medicamentosas)

  • Miconazolantifúngico azólicoLeve

    Development of Potential for Microbial Overgrowth Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with metronidazole and requires treatment with an antifungal agent. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Advertencias y precauciones)

  • TerbinafinaantifúngicoLeve

    Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. (etiqueta de Terbinafina, Interacciones medicamentosas)

  • Vecuroniobloqueador neuromuscularLeve

    The following antibiotics have been associated with various degrees of paralysis: aminoglycosides (such as neomycin, streptomycin, kanamycin, gentamicin, and dihydrostreptomycin); tetracyclines; bacitracin; polymyxin B; colistin; and sodium colistimethate. (etiqueta de Vecuronio, Precauciones)

Sin interacción significativa según la etiqueta (4)

  • AminofilinametilxantinaSin interacción

    …enflurane famotidine felodipine finasteride hydrocortisone isoflurane isoniazid isradipine influenza vaccine ketoconazole lomefloxacin mebendazole medroxyprogesterone methylprednisolone metronidazole metoprolol nadolol nifedipine nizatidine norfloxacin ofloxacin omeprazole prednisone, prednisolone ranitidine rifabutin roxithromycin sorbitol (purgative doses do not… (etiqueta de Aminofilina, Interacciones medicamentosas)

  • Cisatracuriobloqueador neuromuscularSin interacción

    …additional doses of Cisatracurium Besylate Injection, and to determine whether adjustments need to be made to the dose with subsequent administration. † Examples: aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, sodium colistimethate Drug or Drug Class Clinical Implications * Succinylcholine The use of succinylcholine… (etiqueta de Cisatracurio, Interacciones medicamentosas)

  • Neostigminainhibidor de la colinesterasaSin interacción

    There was no effect on neostigmine action on rocuronium reversal by cefuroxime, metronidazole, cefuroxime or metronidazole. (etiqueta de Neostigmina, Interacciones medicamentosas)

  • TeofilinametilxantinaSin interacción

    …clinically significant interaction with theophylline.* albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without methylprednisolone sulbactam metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin… (etiqueta de Teofilina, Interacciones medicamentosas)

Compruebe Subcitrato de bismuto, metronidazol y tetraciclina frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.